tert-butyl (1S,4S)-5-[4-[3-(dimethylamino)prop-2-enoyl]-3-fluorophenyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate | 1186335-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl (1S,4S)-5-[4-[3-(dimethylamino)prop-2-enoyl]-3-fluorophenyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
• CAS: 1186335-10-3
• 化学式: C₂₁H₂₈FN₃O₃
• 分子量: 389.47
• InChiKey: CHTSGDPYMOUKPQ-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  53.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(7-fluoro-1H-indazol-4-yl)-5-pyridin-4-yl-2H-pyrazol-3-ylamine 、 tert-butyl (1S,4S)-5-[4-[3-(dimethylamino)prop-2-enoyl]-3-fluorophenyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 在 三氟乙酸 作用下， 以 甲醇 为溶剂， 生成 5-{3-fluoro-4-[3-(7-fluoro-1H-indazol-4-yl)-2-pyridin-4-yl-pyrazolo[1,5-a]pyrimidin-7-yl]-phenyl}-2,5-diaza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity

  摘要：

  Novel indazolylpyrazolo[1,5-a]pyrimidine analogues have been prepared and found to be extremely potent type I B-Raf inhibitors. The lead compound shows good selectivity against a panel of 60 kinases, possesses a desirable pharmacokinetic profile, and demonstrates excellent in vivo antitumor efficacy in B-Raf mutant xenograft models.

  DOI：

  10.1021/jm1007566

文献信息

• BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF
  申请人：Wyeth LLC

  公开号：EP2271649A1

  公开（公告）日：2011-01-12
• Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity
  作者：Xiaolun Wang、Dan M. Berger、Edward J. Salaski、Nancy Torres、Minu Dutia、Cilien Hanna、Yongbo Hu、Jeremy I. Levin、Dennis Powell、Donald Wojciechowicz、Karen Collins、Eileen Frommer、Judy Lucas

  DOI：10.1021/jm1007566

  日期：2010.11.11

  Novel indazolylpyrazolo[1,5-a]pyrimidine analogues have been prepared and found to be extremely potent type I B-Raf inhibitors. The lead compound shows good selectivity against a panel of 60 kinases, possesses a desirable pharmacokinetic profile, and demonstrates excellent in vivo antitumor efficacy in B-Raf mutant xenograft models.